Chinese 3SBio goes private; Sanofi's Gaucher disease drug moves forward;

 @FierceBiotech: Still trending: The 25 most influential people in biopharma today - 2013. Special Report | Follow @FierceBiotech

@JohnCFierce: Mega-mergers are back (expect 1-2 big deals in biopharma this year). News | Follow @JohnCFierce

@RyanMFierce: Japan takes lead in trialing a human stem cell therapy. Story | Follow @RyanMFierce

> Chinese biotech company 3SBio has struck a $340 million deal to be taken private by the Chinese CITIC Private Equity. Story

> Amicus Therapeutics ($FOLD) announced more results from its ongoing PhIII trial of its investigational oral migalastat HCl monotherapy in patients with Fabry disease. Release

> Modulation Therapeutics has received an undisclosed amount of seed funding from the Institute for the Commercialization of Public Research to help further develop a therapy for myeloma, an incurable blood cancer. Release

> Janssen has partnered with the U.K.'s National Health Service for a new program aimed at advancing dementia care. Story

> Sanofi ($SNY) says its experimental pill for Gaucher disease met its main targets in two late-stage studies, moving it closer to regulatory approval. Story

Pharma News

@FiercePharma: Shire's Vyvanse tops $1B as more generics challenge Adderall. Report | Follow @FiercePharma

@EricPFierce: Mylan currently the focus of a hot rumor for picking up the sterile injectables unit of India's Strides Arcolab. News | Follow @EricPFierce

@AlisonBFierce: A promising new vaccine--administered as a nasal spray--is shrinking head and neck tumors. More | Follow @AlisonBFierce

> Seroquel XR patent upheld, protecting AZ blockbuster. News

> Premium pricing for Novo's Tresiba in EU, a tiny bit of good news. Story

> Congressmen want FDA to act now on restricting painkillers. Item

Medical Device News

 @FierceMedDev: Cohera snags $17M to support TissuGlu. News | Follow @FierceMedDev

 @MarkHFierce: Weight loss devices never go out of style. BAROnova secured a $27.3M Series C for its contribution to the space. More | Follow @MarkHFierce

 @DamianFierce: St. Jude is studying whether renal denervation can treat heart attack and stroke in addition to hypertension. Press release | Follow @DamianFierce

> Acquisitions help boost Alere's 2012 Q4 revenue. Item

> J&J braces international market for more metal hip problems. Article

> Second Sight scores victory with FDA nod for retinal prosthesis. News

And Finally... Swedish fish come out of their shells--so to speak--with anti-anxiety drug. Story

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.